Neuroene Therapeutics Co-Founder and CEO Sherine Chan, Ph.D., joins Rich Bendis on BioTalk to discuss winning the 7th Annual BioHealth Capital Region Crab Trap, their drug discovery platform and being located at JLABS @ Washington, DC.
Listen now via Google bit.ly/3D5tm9O, apple.co/3eGzXy7, or Spotify spoti.fi/3D6lgOx.
Sherine Chan is the CEO and Co-Founder of Neuroene Therapeutics, a biotech company developing novel mitochondrial therapeutics for difficult-to-treat neurological diseases. She is a mitochondrial biologist with a B.Sc. Hons. degree in Veterinary Biology (Murdoch University, Australia) and a Ph.D. in Clinical Biochemistry (University of Western Australia).
After her postdoctoral fellowship on mitochondrial diseases at NIEHS/NIH in Research Triangle Park, NC, she moved to the Medical University of South Carolina (MUSC) in Charleston, SC, to start her lab in the Department of Drug Discovery and Biomedical Sciences, where she rose to Associate Professor. Her group developed new animal models and assays of mitochondrial dysfunction to understand the progression of mitochondrial disease in early life, and to screen novel mitochondrial-active compounds. During this time, she and a medicinal chemist at MUSC, Dr. James Chou, discovered that small Vitamin K analogs were neuroactive and had potent activity in animal models of seizure, Parkinson's Disease, and mitochondrial disease, leading them to co-found Neuroene Therapeutics.
Dr. Chan now runs Neuroene Therapeutics full-time and recently moved the company to JLABS @ Washington, DC, as Neuroene was selected to join the Blue Knight Program, a joint initiative between Johnson & Johnson Innovation JLABS and BARDA.